BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Innovations | Feb 22, 2019
Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
BC Innovations | Jun 28, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer In vitro , cell culture and mouse studies identified two benzenesulfonamide-based AXL inhibitors that could help treat breast cancer. Chemical synthesis and in vitro enzymatic activity assays of benzenesulfonamide analogs yielded two compounds...
BC Innovations | Jan 25, 2018
Targets & Mechanisms

Unexpected combinations

Two studies are prompting a rethink of how combination therapies target cancer at both the level of individual cells, and across a patient population. The papers are pushing drug developers to parse data from preclinical...
BC Extra | Jan 15, 2018
Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in Nature Medicine , Genmab A/S (CSE:GEN; Pink:GMXAY) and academic researchers identified a combination therapy approach that could combat drug resistance in heterogeneous tumors. Melanoma tumors with BRAF mutations that are --...
BioCentury | Dec 9, 2017
Strategy

Genmab’s second act

For the second time, Genmab A/S finds itself at the threshold of transitioning into a commercial biotech and is planning to change its partnering approach to retain a more significant portion of the value of...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
BC Innovations | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

With its development of an AXL decoy able to trap and sequester the native receptor’s ligand with femtomolar affinity, Aravive Biologics Inc. believes it has a biologic that can bypass the potency and selectivity issues...
BC Extra | Dec 10, 2015
Top Story

Genmab describes Darzalex-fueled pipeline

Genmab A/S (CSE:GEN; OTCBB:GMXAY) hopes to put at least four new candidates into the clinic over the next four years using revenue from newly approved multiple myeloma (MM) drug Darzalex daratumumab . The company also presented...
BC Week In Review | Sep 22, 2014
Company News

Seattle Genetics, Genmab deal

Seattle Genetics granted Genmab rights to use antibody-drug conjugate (ADC) technology with Genmab's cancer candidate HuMax-AXL-ADC , an ADC against AXL receptor tyrosine kinase (AXL; UFO). Genmab will receive $11 million up front and is eligible...
Items per page:
1 - 10 of 10